Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZR2 vs R-miniCHOP in Elderly Unfit/Frail DLBCL
NCT05179733Phase 3Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Mar 2022
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 3 trial of zanubrutinib, lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Started Mar 2022; status: recruiting.
02
Drugs
zanubrutiniblenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05179733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179733.